Biohaven Pharmaceutical Holding Company Ltd.
NYSE:BHVN
39.31 (USD) • At close February 4, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Assets: | |||||||
| Current Assets: | |||||||
| Cash & Cash Equivalents
| 248.402 | 204.877 | 76.057 | 82.506 | 316.727 | 264.249 | 131.468 |
| Short Term Investments
| 133.417 | 260.464 | 192.648 | 223.185 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 381.819 | 465.341 | 76.057 | 82.506 | 316.727 | 264.249 | 131.468 |
| Net Receivables
| 13.648 | 46.139 | 9.911 | 0 | 0 | 0 | 0 |
| Inventory
| -0.396 | 56.157 | 6.734 | 39.563 | 0 | 0 | 0 |
| Other Current Assets
| 47.375 | 75.488 | 8.855 | 7.25 | 11.554 | 8.09 | 5.197 |
| Total Current Assets
| 442.446 | 586.968 | 94.823 | 89.756 | 328.281 | 272.339 | 136.665 |
| Non-Current Assets: | |||||||
| Property, Plant & Equipment, Net
| 48.576 | 52.44 | 18.232 | 13.56 | 8.152 | 6.248 | 2.344 |
| Goodwill
| 1.39 | 1.39 | 1.39 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 18.4 | 18.4 | 18.4 | 39.087 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 19.79 | 19.79 | 19.79 | 39.087 | 0 | 0 | 0 |
| Long Term Investments
| 2.4 | 2.398 | 6 | 7.176 | 0 | 0 | 0 |
| Tax Assets
| -2.4 | -2.398 | 0 | -39.087 | 0 | 0 | 0 |
| Other Non-Current Assets
| 0 | 2.585 | 3.216 | 1.007 | 7.831 | 11.425 | 7.879 |
| Total Non-Current Assets
| 70.766 | 74.815 | 47.238 | 21.743 | 15.983 | 17.673 | 10.223 |
| Total Assets
| 513.212 | 661.783 | 142.061 | 111.499 | 344.264 | 290.012 | 146.888 |
| Liabilities & Equity: | |||||||
| Current Liabilities: | |||||||
| Account Payables
| 15.577 | 10.703 | 4.775 | 2.758 | 14.071 | 10.752 | 4.721 |
| Short Term Debt
| 3.308 | 3.019 | 0 | 0.675 | 0 | 0 | 0 |
| Tax Payables
| 0 | 38.165 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | -38.231 | -0.439 | -0.675 | 0 | 0 | 0 |
| Other Current Liabilities
| 36.538 | 38.134 | 37.16 | 26.444 | 52.102 | 8.782 | 4.708 |
| Total Current Liabilities
| 55.423 | 90.021 | 41.935 | 29.877 | 66.173 | 19.534 | 9.429 |
| Non-Current Liabilities: | |||||||
| Long Term Debt
| 27.569 | 30.581 | 2.797 | 270.387 | 0 | 117.515 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 2.245 | 2.41 | 2.638 | -265.546 | 285.515 | 2.043 | 5.488 |
| Total Non-Current Liabilities
| 29.814 | 32.991 | 5.435 | 4.841 | 285.515 | 119.558 | 5.488 |
| Total Liabilities
| 85.237 | 123.012 | 47.37 | 34.718 | 351.688 | 139.092 | 14.917 |
| Equity: | |||||||
| Preferred Stock
| 0 | 0 | 774.071 | 407.151 | 0 | 0 | 0 |
| Common Stock
| 887.528 | 615.742 | 1,676.792 | 1,249.547 | 881.426 | 554.384 | 311.061 |
| Retained Earnings
| -499.292 | -91.124 | -2,585.755 | -1,739.169 | -972.373 | -443.568 | -202.646 |
| Accumulated Other Comprehensive Income/Loss
| -0.065 | 0.284 | -0.073 | 0.314 | 0 | 0 | 0 |
| Other Total Stockholders Equity
| 39.804 | 13.869 | 0 | 0 | 83.523 | 40.104 | 23.556 |
| Total Shareholders Equity
| 427.975 | 538.771 | 34.691 | 16.781 | -7.424 | 150.92 | 131.971 |
| Total Equity
| 427.975 | 538.771 | 94.691 | 76.781 | -7.424 | 150.92 | 131.971 |
| Total Liabilities & Shareholders Equity
| 513.212 | 661.783 | 142.061 | 111.499 | 344.264 | 290.012 | 146.888 |